Randomized, double-blind, placebo-controlled study on FPF1100NW monotherapy with early Parkinson's disease patients (Phase III study)
Latest Information Update: 10 Jun 2016
At a glance
- Drugs Selegiline (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors FP Pharmaceutical Corp
- 10 Jun 2016 New trial record